Logo image of ENZ

ENZO BIOCHEM INC (ENZ) Stock Fundamental Analysis

USA - NYSE:ENZ - US2941001024 - Common Stock

0.3138 USD
-0.07 (-17.77%)
Last: 4/17/2025, 8:15:28 PM
0.32 USD
+0.01 (+1.98%)
After Hours: 4/17/2025, 8:15:28 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ENZ. ENZ was compared to 101 industry peers in the Health Care Providers & Services industry. While ENZ seems to be doing ok healthwise, there are quite some concerns on its profitability. ENZ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ENZ has reported negative net income.
In the past year ENZ has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ENZ reported negative net income in multiple years.
In the past 5 years ENZ reported 4 times negative operating cash flow.
ENZ Yearly Net Income VS EBIT VS OCF VS FCFENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

ENZ has a worse Return On Assets (-31.57%) than 86.67% of its industry peers.
The Return On Equity of ENZ (-45.72%) is worse than 71.43% of its industry peers.
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROIC N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ENZ Yearly ROA, ROE, ROICENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

ENZ has a Gross Margin of 44.74%. This is in the better half of the industry: ENZ outperforms 74.29% of its industry peers.
In the last couple of years the Gross Margin of ENZ has grown nicely.
The Profit Margin and Operating Margin are not available for ENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
ENZ Yearly Profit, Operating, Gross MarginsENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

5

2. Health

2.1 Basic Checks

ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENZ has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENZ has been increased compared to 5 years ago.
ENZ has a better debt/assets ratio than last year.
ENZ Yearly Shares OutstandingENZ Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENZ Yearly Total Debt VS Total AssetsENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.09, we must say that ENZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.09, ENZ is doing worse than 87.62% of the companies in the same industry.
ENZ has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, ENZ belongs to the best of the industry, outperforming 84.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.09
ROIC/WACCN/A
WACC9.89%
ENZ Yearly LT Debt VS Equity VS FCFENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

ENZ has a Current Ratio of 3.04. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 3.04, ENZ belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
ENZ has a Quick Ratio of 2.69. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.69, ENZ belongs to the best of the industry, outperforming 81.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.69
ENZ Yearly Current Assets VS Current LiabilitesENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

ENZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -430.17%.
ENZ shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -54.20%.
The Revenue for ENZ have been decreasing by -17.04% on average. This is quite bad
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENZ Yearly Revenue VS EstimatesENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ENZ Yearly EPS VS EstimatesENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2022 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ENZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENZ Price Earnings VS Forward Price EarningsENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENZ Per share dataENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 31.87%, ENZ is a good candidate for dividend investing.
The stock price of ENZ dropped by -52.09% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 2.45, ENZ pays a better dividend. On top of this ENZ pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, ENZ pays a better dividend.
Industry RankSector Rank
Dividend Yield 31.87%

5.2 History

ENZ does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ENZ Yearly Dividends per shareENZ Yearly Dividends per shareYearly Dividends per share 2024 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ENZ Yearly Income VS Free CF VS DividendENZ Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

More info and screens

ENZO BIOCHEM INC

NYSE:ENZ (4/17/2025, 8:15:28 PM)

After market: 0.32 +0.01 (+1.98%)

0.3138

-0.07 (-17.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)06-11 2025-06-11
Inst Owners34.1%
Inst Owner Change0%
Ins Owners10.57%
Ins Owner Change0%
Market Cap16.44M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 31.87%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.56
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.74%
FCFM N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.14%
Cap/Sales 2.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.69
Altman-Z -5.09
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)89.52%
Cap/Depr(5y)102.77%
Cap/Sales(3y)7.08%
Cap/Sales(5y)5.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.68%
OCF growth 3YN/A
OCF growth 5YN/A